Royalty Pharma plc

RPRX

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001814876-26-000012
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026
Reporting Owners: Coyne Terrance P. (CFO)

Summary

Type

Sell

Net shares

-34,791

% of shares

-15.15%

Amount (USD)

$1,627,533

Insider confidence score

18.8 out of 100

Positive

  • Under Rule 10b5-1 trading plan

Negative

  • Massive scheduled sell (<20% of shares)
  • Very large sell amount ($1M+)

Stock transactions

Transaction 1

Security

Class A Ordinary Shares

Action

Sell

Date

2026-03-02

Code

S

Net shares

-22,487.0

Price per Share

$46.67

Amount (USD)

$1,049,506.52

Acquired/Disposed

Disposed

Shares Owned Before

131,664.0

Shares Owned After

109,177.0

Transaction 2

Security

Class A Ordinary Shares

Action

Sell

Date

2026-03-02

Code

S

Net shares

-10,429.0

Price per Share

$47.01

Amount (USD)

$490,314.22

Acquired/Disposed

Disposed

Shares Owned Before

109,177.0

Shares Owned After

98,748.0

Transaction 3

Security

Class A Ordinary Shares

Action

Sell

Date

2026-03-02

Code

S

Net shares

-1,292.0

Price per Share

$46.67

Amount (USD)

$60,303.71

Acquired/Disposed

Disposed

Shares Owned Before

47,636.0

Shares Owned After

46,344.0

Transaction 4

Security

Class A Ordinary Shares

Action

Sell

Date

2026-03-02

Code

S

Net shares

-583.0

Price per Share

$47.01

Amount (USD)

$27,409.34

Acquired/Disposed

Disposed

Shares Owned Before

46,344.0

Shares Owned After

45,761.0

Filing's footnotes

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

ℹ️ Filed under Rule 10b5-1 trading plan

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.